Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.
about
Dietary advice for people with schizophreniaPatient outcomes following discharge from secure psychiatric hospitals: systematic review and meta-analysisPharmacological mechanisms underlying the association of antipsychotics with metabolic disordersMetabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies.Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Smartphone Apps for Schizophrenia: A Systematic Review.The Prevalence of Metabolic Syndrome and Its Related Factors among Adults in Palestine: A Meta-Analysis.Exercise therapy in adults with serious mental illness: a systematic review and meta-analysisBayesian semiparametric copula estimation with application to psychiatric geneticsThe contribution of abdominal obesity and dyslipidemia to metabolic syndrome in psychiatric patients.Factors affecting hospital stay in psychiatric patients: the role of active comorbidity.Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors.Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?Pharmacological treatment of ambulatory schizophrenic patients in BelgiumPrevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional studyImproving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trialSafety and tolerability of antipsychotics: focus on amisulpride.Metformin and berberine prevent olanzapine-induced weight gain in ratsSoluble urokinase-type plasminogen activator receptor levels in patients with schizophreniaMetabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses.Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up studyDiabetes and glucose disturbances in patients with psychosis in Sweden.High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide SurveyEfficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Metabolic syndrome in patients with severe mental illness in GorganCardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.A case series: evaluation of the metabolic safety of aripiprazoleCardiovascular effects of antipsychotics.A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidoneEffects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.Lifestyle related factors & impact of metabolic syndrome on quality of life, level of functioning & self-esteem in patients with bipolar disorder & schizophrenia.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Metabolic syndrome in people with schizophrenia: a review.The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs.Metabolic syndrome in schizophrenia.Metabolic syndrome and central obesity in depression: A cross-sectional study.A UK audit of screening for the metabolic side effects of antipsychotics in community patients.
P2860
Q24186009-05C50661-5347-40DD-89CA-3CDC6C2292CDQ26771219-8EF81188-C9F6-4D2D-AF58-D9B0A70F9598Q26999668-D223262A-FDDD-4091-9308-5498EA8F92E8Q30736365-EEFACBC2-F7CB-486F-8742-5769E09418BEQ31145823-20A6BC5B-6AF3-49F3-8270-DEF14AD0FE5EQ33445829-44BD40DC-DC96-4542-9CE3-F1B6AC56D596Q33559826-5F646F36-6689-40FF-AA92-934BAE90D9F6Q33600284-17466959-7E2B-4BEA-9082-6BDB56BE1B06Q33867602-26011602-EC06-4483-AA9D-96CB62DA313DQ33893935-646AF10A-BF9F-490B-8EC4-E70EDA73C3D6Q34309209-B8B6D137-9835-48F0-BA2A-505384450FCAQ34325802-CCDDCDB3-5968-4494-AD94-1D6829EB8260Q34523972-92B49B4E-FB61-45BC-9F16-7D80F90DDE65Q34623350-D1FB2ADF-C967-4DC3-95F9-8197B2406574Q34634393-84114521-84F3-4BD6-A102-11C139366261Q34691376-B2EAB345-21FC-4EBB-97BF-CA9B338D2504Q34944648-337A8EF8-562A-4F12-9BE4-044C436C0691Q35019136-7941596E-9FDC-4558-B91D-432D8067BCC9Q35026487-81807AD0-3A04-4B99-90F7-728F4AA16FE3Q35131343-5C4D6959-1685-442D-BAD2-1CCA0A2C6A15Q35369617-FF52BADC-FAA4-4208-9044-162257DC8242Q35530406-E4E81B41-7E6D-40B1-A802-A054B3015C1BQ35793800-0649739A-9658-46CE-B6CF-37ED00AA83E8Q36143815-E1C7F995-64C3-4DA6-B33D-EE9709E5E92FQ36195246-0166653A-B5CB-4250-8B7F-2230D58B122AQ36232038-8FC91DE8-E1B0-4CCE-AE3C-8DD733F6EE82Q36474147-518BAC87-B6FC-49AA-9FA1-B867FED6DEB8Q36657453-F2CBA312-7DEA-4A5F-97B8-C6BAB135E0ADQ36714070-9E08BFA9-88CA-453C-8FE6-D4355A6B1E36Q36853249-32069D92-3049-4469-8F1D-32D9CFE386D8Q36870063-F08288CF-9CC9-423F-837F-63D53043142EQ36989599-C6DCFA0D-FC06-4227-9F34-714B07F900C2Q37029513-3E772749-43CB-4113-92DF-0BDB2A347568Q37055414-FB6EA91D-0662-4306-AEB7-A08B47A74F25Q37079080-D7187584-5B63-4F4D-860D-17655BF7E52DQ37129646-91BB8FD8-BBC1-49A4-AA99-2714356007E0Q37148732-FC216A6C-ECE7-445E-B06F-328D9ED66CAAQ37290165-57DF9123-6A2D-47E5-BFDB-0FF95CDC6104Q37400542-F3588FD1-66ED-4B31-99A2-96D3386F5571Q37427104-8E9CBBBE-4562-49D9-B1CF-4DB9DF47F39A
P2860
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Prevalence of the metabolic sy ...... with antipsychotic medication.
@en
Prevalence of the metabolic sy ...... with antipsychotic medication.
@nl
type
label
Prevalence of the metabolic sy ...... with antipsychotic medication.
@en
Prevalence of the metabolic sy ...... with antipsychotic medication.
@nl
prefLabel
Prevalence of the metabolic sy ...... with antipsychotic medication.
@en
Prevalence of the metabolic sy ...... with antipsychotic medication.
@nl
P2093
P921
P1476
Prevalence of the metabolic sy ...... with antipsychotic medication.
@en
P2093
Andre Scheen
Dominique Van Eyck
Linda Hanssens
Marc A De Hert
Martien Wampers
Ruud van Winkel
P356
10.1016/J.SCHRES.2005.12.855
P407
P577
2006-02-14T00:00:00Z